A novel serum microRNA panel to discriminate benign from malignant ovarian disease.

Hdl Handle:
http://hdl.handle.net/10147/565660
Title:
A novel serum microRNA panel to discriminate benign from malignant ovarian disease.
Authors:
Langhe, Ream; Norris, Lucy; Saadeh, Feras Abu; Blackshields, Gordon; Varley, Rachel; Harrison, Ashling; Gleeson, Noreen; Spillane, Cathy; Martin, Cara; O'Donnell, Dearbhaile M; D'Arcy, Tom; O'Leary, John; O'Toole, Sharon
Citation:
A novel serum microRNA panel to discriminate benign from malignant ovarian disease. 2015, 356 (2 Pt B):628-36 Cancer Lett.
Journal:
Cancer letters
Issue Date:
28-Jan-2015
URI:
http://hdl.handle.net/10147/565660
DOI:
10.1016/j.canlet.2014.10.010
PubMed ID:
25451316
Abstract:
Ovarian cancer is the seventh most common cancer in women and the most frequent cause of gynaecological malignancy-related mortality in women. Currently, no standardized reliable screening test exists. MicroRNA profiling has allowed the identification of signatures associated with diagnosis, prognosis and response to treatment of human tumours. The aim of this study was to determine if a microRNA signature could distinguish between malignant and benign ovarian disease. A training set of 5 serous ovarian carcinomas and 5 benign serous cystadenomas were selected for the initial experiments. The validation set included 20 serous ovarian carcinomas and 20 benign serous cystadenomas. The serum/plasma focus microRNA Exiqon panel was used for the training set. For the validation set a pick and mix Exiqon panel, which focuses on microRNAs of interest was used. A panel of 4 microRNAs (let-7i-5p, miR-122, miR-152-5p and miR-25-3p) was significantly down regulated in cancer patients. These microRNAs target WNT signalling, AKT/mTOR and TLR-4/MyD88, which have previously been found to play a role in ovarian carcinogenesis and chemoresistance. let-7i-5p, miR-122, miR-152-5p and miR-25-3p could act as diagnostic biomarkers in ovarian cancer.
Item Type:
Article
Language:
en
MeSH:
Adult; Aged; Aged, 80 and over; Case-Control Studies; Cystadenocarcinoma, Serous; Female; Follow-Up Studies; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hemolysis; Humans; Male; MicroRNAs; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Prognosis; RNA, Messenger; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Tumor Markers, Biological
ISSN:
1872-7980

Full metadata record

DC FieldValue Language
dc.contributor.authorLanghe, Reamen
dc.contributor.authorNorris, Lucyen
dc.contributor.authorSaadeh, Feras Abuen
dc.contributor.authorBlackshields, Gordonen
dc.contributor.authorVarley, Rachelen
dc.contributor.authorHarrison, Ashlingen
dc.contributor.authorGleeson, Noreenen
dc.contributor.authorSpillane, Cathyen
dc.contributor.authorMartin, Caraen
dc.contributor.authorO'Donnell, Dearbhaile Men
dc.contributor.authorD'Arcy, Tomen
dc.contributor.authorO'Leary, Johnen
dc.contributor.authorO'Toole, Sharonen
dc.date.accessioned2015-08-05T15:00:50Zen
dc.date.available2015-08-05T15:00:50Zen
dc.date.issued2015-01-28en
dc.identifier.citationA novel serum microRNA panel to discriminate benign from malignant ovarian disease. 2015, 356 (2 Pt B):628-36 Cancer Lett.en
dc.identifier.issn1872-7980en
dc.identifier.pmid25451316en
dc.identifier.doi10.1016/j.canlet.2014.10.010en
dc.identifier.urihttp://hdl.handle.net/10147/565660en
dc.description.abstractOvarian cancer is the seventh most common cancer in women and the most frequent cause of gynaecological malignancy-related mortality in women. Currently, no standardized reliable screening test exists. MicroRNA profiling has allowed the identification of signatures associated with diagnosis, prognosis and response to treatment of human tumours. The aim of this study was to determine if a microRNA signature could distinguish between malignant and benign ovarian disease. A training set of 5 serous ovarian carcinomas and 5 benign serous cystadenomas were selected for the initial experiments. The validation set included 20 serous ovarian carcinomas and 20 benign serous cystadenomas. The serum/plasma focus microRNA Exiqon panel was used for the training set. For the validation set a pick and mix Exiqon panel, which focuses on microRNAs of interest was used. A panel of 4 microRNAs (let-7i-5p, miR-122, miR-152-5p and miR-25-3p) was significantly down regulated in cancer patients. These microRNAs target WNT signalling, AKT/mTOR and TLR-4/MyD88, which have previously been found to play a role in ovarian carcinogenesis and chemoresistance. let-7i-5p, miR-122, miR-152-5p and miR-25-3p could act as diagnostic biomarkers in ovarian cancer.en
dc.language.isoenen
dc.rightsArchived with thanks to Cancer lettersen
dc.subject.meshAdulten
dc.subject.meshAgeden
dc.subject.meshAged, 80 and overen
dc.subject.meshCase-Control Studiesen
dc.subject.meshCystadenocarcinoma, Serousen
dc.subject.meshFemaleen
dc.subject.meshFollow-Up Studiesen
dc.subject.meshGene Expression Profilingen
dc.subject.meshGene Expression Regulation, Neoplasticen
dc.subject.meshHemolysisen
dc.subject.meshHumansen
dc.subject.meshMaleen
dc.subject.meshMicroRNAsen
dc.subject.meshMiddle Ageden
dc.subject.meshNeoplasm Stagingen
dc.subject.meshOvarian Neoplasmsen
dc.subject.meshPrognosisen
dc.subject.meshRNA, Messengeren
dc.subject.meshReal-Time Polymerase Chain Reactionen
dc.subject.meshReverse Transcriptase Polymerase Chain Reactionen
dc.subject.meshTumor Markers, Biologicalen
dc.titleA novel serum microRNA panel to discriminate benign from malignant ovarian disease.en
dc.typeArticleen
dc.identifier.journalCancer lettersen
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.